Revvity/$RVTY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Revvity
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
Ticker
$RVTY
Sector
Primary listing
NYSE
Employees
11,000
Headquarters
Website
Revvity Metrics
BasicAdvanced
$9.8B
35.49
$2.37
0.92
$0.28
0.33%
Price and volume
Market cap
$9.8B
Beta
0.92
52-week high
$128.29
52-week low
$81.36
Average daily volume
1.2M
Dividend rate
$0.28
Financial strength
Current ratio
3.329
Quick ratio
2.46
Long term debt to equity
44.661
Total debt to equity
44.664
Dividend payout ratio (TTM)
11.88%
Interest coverage (TTM)
4.59%
Profitability
EBITDA (TTM)
840.062
Gross margin (TTM)
55.92%
Net profit margin (TTM)
10.19%
Operating margin (TTM)
15.26%
Effective tax rate (TTM)
11.80%
Revenue per employee (TTM)
$250,000
Management effectiveness
Return on assets (TTM)
2.05%
Return on equity (TTM)
3.61%
Valuation
Price to earnings (TTM)
35.49
Price to revenue (TTM)
3.616
Price to book
1.29
Price to tangible book (TTM)
-6.21
Price to free cash flow (TTM)
20.12
Free cash flow yield (TTM)
4.97%
Free cash flow per share (TTM)
4.175
Dividend yield (TTM)
0.33%
Forward dividend yield
0.33%
Growth
Revenue change (TTM)
3.33%
Earnings per share change (TTM)
72.56%
3-year revenue growth (CAGR)
-9.28%
10-year revenue growth (CAGR)
2.25%
3-year earnings per share growth (CAGR)
-24.24%
10-year earnings per share growth (CAGR)
5.10%
What the Analysts think about Revvity
Analyst ratings (Buy, Hold, Sell) for Revvity stock.
Bulls say / Bears say
Revvity topped first-quarter revenue and EPS estimates, posting $664.8 million in sales against the $661.2 million consensus and adjusted EPS of $1.01 versus $0.95. The company also raised its 2025 revenue guidance to $2.83–2.87 billion (Reuters)
GAAP operating income from continuing operations climbed to $72.2 million in Q1 from $44.1 million a year before, raising the GAAP operating margin to 10.9% and showcasing strong operational leverage (Revvity Q1 Press Release)
Strategic product innovation expanded diagnostic offerings with the May 2025 launch of the IDS i20 fully-automated immunodiagnostics platform, increasing lab throughput and cross-selling opportunities (Business Wire)
Despite first-quarter outperformance, Revvity shares are down 15.5% year-to-date due to ongoing challenges in biotech funding and continued policy uncertainty from the U.S. administration (Reuters)
RVTY stock fell 7.9% after Q2 earnings when the company lowered its organic growth outlook to 2–4% and cut its full-year adjusted EPS forecast to $4.85–$4.95, below analyst expectations (Barron's)
Adjusted operating margin in the second quarter dropped to 26.6% from 28.8% due to higher SG&A and R&D costs, raising concerns about future profitability (Barron's)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.
Revvity Financial Performance
Revenues and expenses
Revvity Earnings Performance
Company profitability
Revvity News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Oct17
Revvity
DividendEx-dividend
Nov7
Revvity
DividendPayment
$0.07Per share
FAQs
What’s the current market cap for Revvity stock?
Revvity (RVTY) has a market cap of $9.8B as of September 16, 2025.
What is the P/E ratio for Revvity stock?
The price to earnings (P/E) ratio for Revvity (RVTY) stock is 35.49 as of September 16, 2025.
Does Revvity stock pay dividends?
Yes, the Revvity (RVTY) stock pays dividends to shareholders. As of September 16, 2025, the dividend rate is $0.28 and the yield is 0.33%. Revvity has a payout ratio of 11.88% on a trailing twelve-month basis.
When is the next Revvity dividend payment date?
The next Revvity (RVTY) dividend payment is scheduled for November 07, 2025.
What is the beta indicator for Revvity?
Revvity (RVTY) has a beta rating of 0.92. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.